Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:16 PM
Ignite Modification Date:
2025-12-24 @ 11:16 PM
NCT ID:
NCT02202356
Eligibility Criteria:
Inclusion Criteria:
* Male or female infant who is ≥1.0 to ≤12.0 months of age (inclusive), defined at the time of hospital admission, or \<28 days of age (neonate cohort only). Note: all subjects, including neonates, must have been discharged from the hospital after birth and are now being admitted due to an RSV related illness
Exclusion Criteria:
* Prematurity
* Receiving invasive endotracheal mechanical ventilation
* Poorly functioning gastrointestinal tract
* Anticipated to be discharged from the hospital in \<24 hours from the time of randomization
* Prior exposure to palivizumab
Healthy Volunteers:
False
Sex:
ALL
Maximum Age:
12 Months
Study:
NCT02202356
Study Brief:
Protocol Section:
NCT02202356